— $9M Second Phase of CDMO Investment Builds on 2025 $6M Expansion, Funding Facility Upgrades and Increased Capacity for Suppository, Semi-Solid,...
Reimagining early-stage drug discovery leveraging NVIDIA BioNeMo Framework -- Persistent Systems (BSE: 533179) (NSE: PERS...
Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease The US Food and Drug Administration (FDA...
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in...
Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a trans...
While companies make decarbonization progress elsewhere, heat has been considered too challenging to progress. - ...
- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study - The enhanced immunosu...
YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene-editing therapies, today announced that the U.S. Food and Drug ...
KOMO Biosciences, a developer of non-viral targeted insertion technologies, today announced that it has granted Syngenta, a world leader in agricultural ...
Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and developm...
As the antibody–drug conjugate (ADC) landscape rapidly evolves, the industry is moving beyond traditional cytotoxic payloads and antibody-first devel...
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform ...
In this BioPharma Boardroom interview, Steven Quay, Founder and CEO of Atossa Therapeutics, outlines the scientific rationale behind developing (Z)-endoxif...
CMIC Co., Ltd., a contract research organization (CRO) jointly owned by Blackstone and CMIC HOLDINGS Co. Ltd., announced a strategic partnership with...
© 2026 Biopharma Boardroom. All Rights Reserved.
